The TxGNN model has no candidate with a score of 0.99 or higher for Entrectinib, so there is currently no new predicted indication. The drug’s recorded uses are listed below.
Quick overview
Item
Content
Known uses recorded for this drug
1
Australia Market Status
Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items
1 (valid: 1)
Known uses recorded for this drug
Approved (supported by a licence or label)
Indication
Source
non-small-cell lung carcinoma
licence in another country
Related to an approved indication (same disease category)
Indication
Approved category
none
none
Relations recorded in the knowledge graph (no approval found)
Indication
none
Australia Market Information
Licence
Product
Dosage form
Status
12092K
Rozlytrek
Capsule 200 mg
Valid
Cytotoxicity
Item
Content
Cytotoxicity Classification
Targeted therapy (kinase inhibitor), not a conventional cytotoxic
Myelosuppression Risk
Please refer to the Product Information (PI) warnings and precautions
Emetogenicity Classification
Please refer to the Product Information (PI) warnings and precautions
Monitoring Items
Please refer to the PI. Haematological parameters, liver and renal function are generally reasonable to monitor.
Handling Protection
Please refer to the PI
Safety Considerations
Label-based warnings and contraindications were not available in the compiled data. Please refer to the TGA-approved Product Information (PI) for these.
Drug interactions: 100 interactions were identified. The major-level ones among those listed include:
Aprepitant
Dexamethasone
Clarithromycin
Dolasetron
Moderate-level interactions include famotidine, loperamide, cimetidine, budesonide, levofloxacin, naltrexone, saxagliptin, empagliflozin and several bowel-preparation agents (bisacodyl, picosulfuric acid, polyethylene glycol, sodium sulfate). Minor-level interactions include naloxegol and metronidazole. Only 20 of the 100 interactions were available for review.
Signals from the literature: A 2025 case report (PMID 41002576) describes pulmonary tumour thrombotic microangiopathy progressing during entrectinib therapy despite tumour response. It is noted as a possible safety or disease-complication concern.
Disclaimer
This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.